Castrate Resistant Prostate Cancer (CRPC) is a difficult entity to treat in the spectrum of prostate cancer disease. Recently, Follicle Stimulating Hormone (FSH) has been shown to play an important part in the natural history of prostate cancer disease progression (Crawford et al. , 2014). Here, we discuss a now deceased 94 year-old patient who illustrates the importance of this.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Urology case reports. 2016 Apr 24*** epublish ***
Salvatore Catarinicchia, E David Crawford
University of Colorado, Division of Urology, 12631 E. 17th Avenue, C-305, Aurora, CO 80045, USA., University of Colorado, Division of Urology, 12631 E. 17th Avenue, C-305, Aurora, CO 80045, USA.